HK7785A - 3-alkylxanthines,process for their preparation and compositions for use in the treatment of chronic obstructive airway diseasse and cardiac disease - Google Patents

3-alkylxanthines,process for their preparation and compositions for use in the treatment of chronic obstructive airway diseasse and cardiac disease

Info

Publication number
HK7785A
HK7785A HK77/85A HK7785A HK7785A HK 7785 A HK7785 A HK 7785A HK 77/85 A HK77/85 A HK 77/85A HK 7785 A HK7785 A HK 7785A HK 7785 A HK7785 A HK 7785A
Authority
HK
Hong Kong
Prior art keywords
methylbutyl
compound
formula
produced
alkylxanthines
Prior art date
Application number
HK77/85A
Other languages
English (en)
Inventor
Per Gunnar Kjellin
Carl Goeran August Persson
Original Assignee
Draco Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Draco Ab filed Critical Draco Ab
Publication of HK7785A publication Critical patent/HK7785A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK77/85A 1978-10-20 1985-01-31 3-alkylxanthines,process for their preparation and compositions for use in the treatment of chronic obstructive airway diseasse and cardiac disease HK7785A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7810947A SE7810947L (sv) 1978-10-20 1978-10-20 3-alkylxanthines

Publications (1)

Publication Number Publication Date
HK7785A true HK7785A (en) 1985-02-08

Family

ID=20336145

Family Applications (1)

Application Number Title Priority Date Filing Date
HK77/85A HK7785A (en) 1978-10-20 1985-01-31 3-alkylxanthines,process for their preparation and compositions for use in the treatment of chronic obstructive airway diseasse and cardiac disease

Country Status (24)

Country Link
US (2) US4548818A (no)
EP (1) EP0010531B1 (no)
JP (1) JPS5557589A (no)
AT (1) ATE1145T1 (no)
AU (1) AU530717B2 (no)
CA (1) CA1131632A (no)
DD (1) DD146708A5 (no)
DE (1) DE2963021D1 (no)
DK (1) DK148884C (no)
ES (1) ES485178A1 (no)
FI (1) FI66867C (no)
GR (1) GR72945B (no)
HK (1) HK7785A (no)
HU (1) HU180220B (no)
IE (1) IE49184B1 (no)
NO (1) NO152561C (no)
NZ (1) NZ191870A (no)
PH (1) PH16676A (no)
PL (1) PL119413B1 (no)
PT (1) PT70350A (no)
SE (1) SE7810947L (no)
SG (1) SG86084G (no)
SU (1) SU952105A3 (no)
ZA (1) ZA795113B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7810947L (sv) * 1978-10-20 1980-04-21 Draco Ab 3-alkylxanthines
SE8002910L (sv) * 1980-04-18 1981-10-19 Draco Ab 3,8-dialkylxantiner, forfarande for deras framstellning, beredning och metoder for behandling av kronisk obstruktiv luftvegssjukdom och kardiovaskulera sjukdomar
CH643260A5 (fr) * 1980-05-02 1984-05-30 Nestle Sa 1-allyl-3-butyl-8-methylxanthine, procede de preparation et utilisation dans un medicament.
IT1200944B (it) * 1982-08-10 1989-01-27 Malesci Sas Derivati xantinici,procedimento per la loro preparazione,composizione farmaceutiche che il contengono e loro impiego terapeutico
US5338741A (en) * 1986-10-27 1994-08-16 Nestec S.A. 1-hydroxyalkylxanthines and medicaments containing them
US5246931A (en) * 1988-10-25 1993-09-21 Bristol-Myers Squibb Company Carbocyclic nucleoside analogs
IL92096A0 (en) 1988-10-25 1990-07-12 Abbott Lab Carboxylic nucleoside analogs
US5153352A (en) * 1988-10-25 1992-10-06 Bristol-Myers Squibb Company Process for preparation of intermediates of carbocyclic nucleoside analogs
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
US5321029A (en) * 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines
IT1229195B (it) * 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
US4988703A (en) * 1989-05-22 1991-01-29 Abbott Laboratories Carbocyclic nucleoside analogs with antiviral activity
CA2030112A1 (en) * 1989-11-24 1991-05-25 Yasuo Ito Xanthine compound, method for preparing thereof, and a pharmaceutical composition comprising the same
FR2657257B1 (fr) * 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
ES2139588T3 (es) * 1991-03-05 2000-02-16 Ajinomoto Kk Derivado de ciclopropano.
US5877179A (en) * 1992-09-29 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
US5786360A (en) * 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
US6376521B1 (en) 1998-07-10 2002-04-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A3 adenosine receptor antagonists
WO2001051490A1 (en) * 2000-01-14 2001-07-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methanocarba cycloalkyl nucleoside analogues
US6623553B2 (en) * 2001-04-20 2003-09-23 John Russell Printing process with edible inks
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
CA2516250A1 (en) 2003-02-19 2004-09-02 Endacea, Inc. A1 adenosine receptor antagonists
WO2005009343A2 (en) * 2003-06-06 2005-02-03 Endacea, Inc. A1 adenosine receptor antogonists
JP2007506804A (ja) * 2003-06-09 2007-03-22 エンダセア， インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
DE102006020519A1 (de) * 2006-05-03 2007-11-08 Robert Bosch Gmbh Vorrichtung zum Einfalten zumindest einer Lasche einer Verpackung
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US7743683B2 (en) * 2006-08-15 2010-06-29 Umagination Labs, L.P. Systems and methods of a power tool system with interchangeable functional attachments powered by a direct rotational drive
WO2011068978A1 (en) 2009-12-02 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives and dendrimer conjugates thereof
US11225481B2 (en) * 2015-12-29 2022-01-18 Centre National De La Recherche Scientifique Xanthine derivative inhibitors of BET proteins

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1245969B (de) * 1967-08-03 VEB Arzneimittelwerk Dresden, Radebeul Verfahren zur Herstellung von Xanthinderivaten
DE864868C (de) * 1943-10-02 1953-01-29 Hellmut Dr Bredereck Verfahren zur Herstellung von Purinverbindungen
US2646432A (en) * 1947-01-13 1953-07-21 Mallinckrodt Chemical Works Method of preparing 2, 6-diketopurines
US2517410A (en) * 1947-08-15 1950-08-01 Searle & Co Hydroxy alkyl xanthines and the production thereof
GB683523A (en) * 1948-08-18 1952-12-03 Beecham Res Lab The manufacture of purine derivatives
US2781344A (en) * 1953-05-04 1957-02-12 Monsanto Chemicals Formylation of amino-pyrimidines
US2844576A (en) * 1955-11-22 1958-07-22 American Cyanamid Co Preparation of purines
BE592753A (no) * 1959-07-09 1900-01-01
GB982079A (en) * 1962-05-01 1965-02-03 Dresden Arzneimittel Process for the production of xanthine derivatives
GB1008454A (en) * 1963-03-26 1965-10-27 Dresden Arzneimittel Pseudoxanthines
JPS53890B2 (no) * 1972-04-22 1978-01-12
GB1435916A (en) * 1972-05-11 1976-05-19 Beecham Group Ltd Pharmaceutical weight-reducing compositions
JPS5125009U (no) * 1974-08-14 1976-02-24
FR2346244A1 (fr) * 1976-03-30 1977-10-28 Chamagne Pierre Nouveau conditionnement pour la conservation de liquides alimentaires
US4089959A (en) * 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents
CA1077932A (en) * 1976-03-31 1980-05-20 Berlex Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
US4120947A (en) * 1976-03-31 1978-10-17 Cooper Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
JPS52133295U (no) * 1976-04-05 1977-10-11
JPS5618169Y2 (no) * 1976-09-20 1981-04-28
SE416810C (sv) * 1977-10-14 1982-07-19 Draco Ab Forfarande for framstellning av xantinderivat med antiallergisk aktivitet
SE7810946L (sv) * 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
SE7810947L (sv) * 1978-10-20 1980-04-21 Draco Ab 3-alkylxanthines
US4338319A (en) * 1979-11-27 1982-07-06 Aktiebolaget Draco Method for the treatment of chronic obstructive airway or cardiac diseases
SE8002910L (sv) * 1980-04-18 1981-10-19 Draco Ab 3,8-dialkylxantiner, forfarande for deras framstellning, beredning och metoder for behandling av kronisk obstruktiv luftvegssjukdom och kardiovaskulera sjukdomar

Also Published As

Publication number Publication date
PL219065A1 (no) 1980-06-16
SE7810947L (sv) 1980-04-21
NO793377L (no) 1980-04-22
IE791987L (en) 1980-04-20
FI793224A (fi) 1980-04-21
DK148884B (da) 1985-11-04
CA1131632A (en) 1982-09-14
HU180220B (en) 1983-02-28
ATE1145T1 (de) 1982-06-15
EP0010531B1 (en) 1982-06-02
DD146708A5 (de) 1981-02-25
SU952105A3 (ru) 1982-08-15
PL119413B1 (en) 1981-12-31
PH16676A (en) 1983-12-13
NO152561B (no) 1985-07-08
ZA795113B (en) 1980-10-29
US4548818A (en) 1985-10-22
JPS5557589A (en) 1980-04-28
SG86084G (en) 1985-06-07
DK432179A (da) 1980-04-21
GR72945B (no) 1984-01-17
AU530717B2 (en) 1983-07-28
NZ191870A (en) 1984-07-06
US4644001A (en) 1987-02-17
JPH0130834B2 (no) 1989-06-22
AU5187179A (en) 1980-05-01
FI66867C (fi) 1984-12-10
PT70350A (en) 1979-11-01
DE2963021D1 (en) 1982-07-22
ES485178A1 (es) 1980-05-16
IE49184B1 (en) 1985-08-21
DK148884C (da) 1986-04-07
EP0010531A1 (en) 1980-04-30
FI66867B (fi) 1984-08-31
NO152561C (no) 1985-10-16

Similar Documents

Publication Publication Date Title
DE2963021D1 (en) 3-alkylxanthines, processes for their preparation and compositions for use in the treatment of chronic obstructive airway disease and cardiac disease
HUT50820A (en) Process for producing purine derivatives with antiviral effect
EP0045094A1 (en) Intermediates for the preparation of therapeutically active xanthine derivatives
PT72881A (en) Process for preparing 3,8-dialkylxanthines and pharmaceutical compositions thereof useful for the treatment of chronic obstructive airway disease and cardiovascular diseases
DE2854015B2 (de) Verfahren zur Herstellung von !H-TetrazoI-1-essigsauren und bestimmter Ester derselben
US4544556A (en) Xanthine derivatives, pharmaceutical compositions containing same and their therapeutic use
Stephen et al. 849. Syntheses in the quinazolone series. Part IV. The conversion of N-aroylorthanilamides into 2-arylquinazol-4-ones
DE1795151B2 (de) 7- eckige Klammer auf D-alpha-Amino-(3-actamidophenylacetamido) eckige Klammer zu -cephalosporansäure
CA2012313C (en) Thienylacetic acid derivatives, process for the preparation thereof, the use thereof, and pharmaceuticals containing these and the preparation thereof
JPS59500B2 (ja) クレアチンの製造法
IE49624B1 (en) Intermediates for the preparation of xanthine derivatives for use in the treatment of chronic obstructive airway disease and cardiac disease
OWEN et al. Studies on the Chemistry of Heterocyclics. X. Syntheses of Thenal-and Thenyl-Barbituric Acids
JPS5651481A (en) 6-cyano-2-oxo-3-methyl-2,3-dihydropurine
JPS565499A (en) Preparation of thymine derivative
JPS5513216A (en) Preparation of 1-(5-oxohexyl)-3,7-dimethylxanthine
CA1075693A (en) Xanthine derivatives
US4113950A (en) Process for preparing orotic acid and thioorotic acid
CA1075691A (en) Xanthine derivatives
JPS5513215A (en) Preparation of 1-(5-oxohexyl)-3,7-dimethylxanthine
Dvornik et al. Preparation of Some lmino-and Cyano-imino-substituted Barbiturates
JPS5492989A (en) Preparation of substituted theobromine
EP0065270A3 (en) Process for the preparation of 7-(2-amino-2-phenylacetamido)cephem derivatives and their use for the preparation of antibacterial agents
JPS55104283A (en) Preparation of 1-(5'-oxyhexyl)-3,7-dimethylxanthine